References
- Vardiman J W, Harris N L, Brunning R D. The World Health Organization (WHO) classification of myeloid neoplasms. Blood 2002; 100: 2292–2302
- Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian H, et al. The biology of chronic myeloid leukemia. N Eng J Med 1999; 34: 164–172
- Calabretta B, Perrotti D. The biology of CML blast crisis. Blood 2004; 103: 4010–4022
- Honda H, Ushijima T, Wakazono K, Oda H, Tanaka Y, Aizawa S, et al. Acquired loss of p53 induces blast transformation in p210 (bcr-abl)-expressing hematopoietic cells. A transgenic study of blast crisis of human CML. Blood 2000; 95: 1144–1150
- Kantarjian H M, Cortes J, O'Brien S, Giles F J, Albitar M, Rios M B, et al. Imatinib mesylate (STI471) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99: 3547–3553
- Bauduer F, Delmer A, Blanc M C, Delmas-Marsalet B, Cadion M, Rio B, et al. Treatment of chronic myelogenous leukemia in blast crisis and in accelerated phase with high- or intermediate-dose cytosine arabinoside and amsacrine. Leuk Lymphoma 1993; 10: 195–200
- Barone S, Baer M R, Sait S N, Lawrence D, Block A W, Wetzler M, et al. High dose cytosine arabinoside and idarubicin treatment of chronic myeloid leukemia in myeloid blast crisis. Am J Hematol 2001; 67: 119–124
- Axdorph U, Stenke L, Grimsfors G, Carnejkog J, Hansen J, Linder O, et al. Intensive chemotherapy in patients with chronic myelogenous leukaemia (CML) in accelerated or blast phase. A report from the Swedish CML group. Br J Haematol 2002; 118: 1048–1055
- Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, et al. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase. Leuk Lymphoma 2007; 48: 283–289
- Kantarjian H, Giles F, Wunderle L, Bhalla M K, O'Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome positive ALL. N Eng J Med 2006; 354: 2542–2551
- Weisberg E, Catley L, Wright R D, Moreno D, Banerji L, Ray A, et al. Beneficial effects of combining nilotinib and imatinib in preclinical models of bcr/abl+ leukemias. Blood October 26, 2006, (Epub ahead of print)
- Fiskus W, Pranpat M, Bali P, Balasis M, Kumaraswamy S, Bajapalle S, et al. Combined effects of novel tyrosine kinase inhibitor AMN107 and histone deacetylase inhibitor LBH589 against bcr-abl-expressing human leukemia cells. Blood 2006; 108: 645–651